WebMoreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly … WebJan 17, 2024 · So, the POLLUX study is also very important for that reason, because we have an incredible number of patients in the relapsed setting achieving MRD negativity. …
Carfilzomib, dexamethasone, and daratumumab versus …
WebApr 8, 2024 · Indeed, the rate of neutropenia in the POLLUX study was higher than that in the CASTOR study [9, 10]. Despite high rates of neutropenia grade 3 or 4, the rate of febrile neutropenia was relatively low (3.8%). Incidence of non-hematological AEs was lower than that reported in clinical trials. WebMay 1, 2024 · In the phase 3 POLLUX study, daratumumab plus lenalidomide and dexamethasone (DRd) significantly reduced the risk of progression/death and induced … mar abierto definicion
Overall Survival With Daratumumab, Lenalidomide, and …
WebJan 17, 2024 · The POLLUX study is a randomized international phase III trial. Again, the highest level of evidence will be used when we assess drugs. It’s based on lenalidomide and dexamethasone in both arms, and the experimental arm has the addition of daratumumab. The results show a median follow-up of 13.5 months. WebJun 12, 2024 · Raritan, N.J., June 12, 2024 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX ® (daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a statistically significant survival … WebMay 12, 2014 · Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies. Haematologica. 2024 Jan 31;105(2):468-477. doi: 10.3324/haematol.2024.217448. Print 2024. cruise cocktail attire